Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05053854 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

Study acronym: PARLuNET
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria revisedv5
  2. Primary and study completion dates: Dec 31, 2025 to Jun 30, 2029v4
  3. Eligibility criteria shortened, about 28 wordsv3
  4. Start date changed from estimate of Sep 27, 2021 to Dec 8, 2021
    • Eligibility criteria shortened, about 13 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase 1 dose-escalation study is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) in patients with metastatic pancreatic or midgut neuroendocrine tumour (NET).
Trial Details
NCT Number NCT05053854
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Conditions
(from sponsor)		 Neuroendocrine Tumors
Related terms Neuroendocrine Tumors
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov